Cost-effective and high-throughput NGS boosts prospects for widespread personalized medicine

The progression of next-generation sequencing (NGS) from research to clinical laboratories is helping to bring the long-awaited goal of personalized medicine one step closer.

Learn more about the Illumina IVD high throughput sequencing instrument. The NovaSeq 6000Dx offers operational simplicity and the flexibility of sequencing in either IVD or research use only (RUO) mode. Paired with the DRAGEN platform, this high throughput solution enables streamlined data handling, delivers faster file transfers, and reduces data storage costs.

Download the article to learn more about how NGS will drive personalized medicine.

For In Vitro Diagnostic Use. Not available in all regions and countries.

Cost-effective and high-throughput NGS boosts prospects for widespread personalized medicine

Image Credit: Illumina, Inc

About Illumina, Inc

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina's innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Sep 7, 2023 at 10:04 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Illumina, Inc.. (2023, September 07). Cost-effective and high-throughput NGS boosts prospects for widespread personalized medicine. News-Medical. Retrieved on October 31, 2024 from https://www.news-medical.net/whitepaper/20230907/Cost-effective-and-High-throughput-NGS-Boosts-Prospects-for-Widespread-Personalized-Medicine.aspx.

  • MLA

    Illumina, Inc.. "Cost-effective and high-throughput NGS boosts prospects for widespread personalized medicine". News-Medical. 31 October 2024. <https://www.news-medical.net/whitepaper/20230907/Cost-effective-and-High-throughput-NGS-Boosts-Prospects-for-Widespread-Personalized-Medicine.aspx>.

  • Chicago

    Illumina, Inc.. "Cost-effective and high-throughput NGS boosts prospects for widespread personalized medicine". News-Medical. https://www.news-medical.net/whitepaper/20230907/Cost-effective-and-High-throughput-NGS-Boosts-Prospects-for-Widespread-Personalized-Medicine.aspx. (accessed October 31, 2024).

  • Harvard

    Illumina, Inc.. 2023. Cost-effective and high-throughput NGS boosts prospects for widespread personalized medicine. News-Medical, viewed 31 October 2024, https://www.news-medical.net/whitepaper/20230907/Cost-effective-and-High-throughput-NGS-Boosts-Prospects-for-Widespread-Personalized-Medicine.aspx.

Other White Papers by this Supplier

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.